| Name | Title | Contact Details |
|---|
Alfa Dental Management is a dental services organization that specializes in implementing highly effective management and business development strategies for dental practices. They partner with dental practices that are positioned for expansion and gro...
Medivators, a wholly owned subsidiary of Cantel Medical Corp. (NYSE:CMN), is a leading provider of infection control products and services that ensure the safe and proper disinfection of endoscopes and other devices. Beyond the full line of Medivators medical device reprocessing systems, disinfectants, detergents and other supplies for endoscopy, Medivators also provides sterilants, dialysate concentrates and other supplies for renal dialysis, hollow fiber membrane filtration and separation technologies for medical and non medical applications and liquid chemical germicides and decontamination products and services used in other applications for infection prevention and control. Medivators new low-temperature sterilization service provides superior material compatibility over legacy sterilization methods. Medivators was founded in 1974 and publicly held since 1983 and employs approximately 400 people.
RANGE MENTAL HEALTH CENTER is a Virginia, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alamance Regional Medical Center, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Alamance Regional Medical Center, Inc. is based in Burlington, NC. You can find more information on Alamance Regional Medical Center, Inc. at www.armc.com
At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.